Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 BR therapy after poor response to R-CHOP in untreated advanced follicular lymphoma
jRCTs051180181Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jun 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bendamustine and rituximab in follicular lymphoma (FL), sponsored by Eisai Co., Ltd. Primary endpoint: Progression-free survival. Started Jun 2013; status: completed.
02
Drugs
bendamustinerituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on jRCTs051180181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180181.